Analyst 8 Mar 21

Tianneng Power trades at only 1/3 the value of its listed subsidiary Tianneng Battery! (8 Mar 2021)

Dear all Tianneng Power (00819.HK) (“TP”) caught my attention recently. It has slumped 40.5% from an intraday high of HKD22.55 on 13 Jan 2021 to close HKD13.42 on 8 Mar 2021. At HKD13.42, it trades at only 1/3 the value of its listed subsidiary Tianneng Battery! Besides this sharp plunge and significant valuation gap, what else does TP have to catch my attention? Read on for more.   First up, a description of TP Quoting from its 1HFY20 results, TP was founded in 1986 and was listed Main Board of The Stock Exchange of Hong Kong Limited as the “First China […]

YZJ Analyst 5 Feb 21

Yangzijiang looks interesting; tests support $0.940 – 0.980 (8 Feb 21)

Yangzijiang (“YZJ”) has weakened approximately 13% from $1.11 on 13 Jan 2021 to close $0.970 on 5 Feb 2021. It has significantly underperformed STI (STI only dropped around 3% over the same period) and is the top STI constituent stocks with the highest potential return (see HERE). Why is it interesting? Read on for more…   Interesting points on YZJ a) Orders are likely to improve in FY21F Based on DBS Research 3 Dec 2020 report, the surge in China (Export) Containerized Freight Index (highest since Mar 2015) and the tripling of the Baltic Dry Index may prompt ship owners […]

Analyst 2 Feb 21

Jiutian – still on an uptrend, tests resistance $0.101 (2 Feb 21)

Dear all With reference to my write-up on Jiutian posted on my blog on 2 Dec 2020 (click HERE), Jiutian touched an intraday low of $0.066 on 14 Dec 2020 before touching an intraday high of $0.116 on 25 & 26 Jan 2021. At the time of this write-up, Jiutian is trading at $0.101 and is on track to test an important resistance $0.101. At current levels, Jiutian seems interesting on the following basis: A) Average selling prices (“ASP”) have improved from the recent low seen in Dec Based on the DMF price as shown on this website (click HERE), […]

Table 1_Ave premium to VWAP

My thoughts on Sing Medical Group’s possible share transaction (29 Dec 20)

Dear all Sing Medical Group (“SMG”) announced on 18 Dec 20 that the Company is currently in discussions with a third party regarding a possible transaction involving the Company’s shares. The discussions are preliminary and there is no certainty or assurance that such discussions will progress beyond the current stage or that any transaction will materialise as a result of such discussions.   Why am I interested in SMG? My personal view is that at $0.315, given a potential share transaction scenario, the risk reward seems favourable. Please refer to my basis and the risks as highlighted below: 1) Past […]

Jiutian 2020 chart 2 Dec 2020

Jiutian – proxy to economic recovery and exposure to EV sector (2 Dec 20)

Dear all Since my write-up “Singapore – Asia’s worst equity market YTD, any opportunities ahead?” posted on my blog on 1 Nov 2020 (click HERE) citing opportunities in our Singapore market, Singapore market (as represented by STI) has clocked in its best monthly return in Nov 2020 since May 2009, up 15.8%! In the U.S., the strong market sentiment is filtering to its small mid cap space with Russell 2000 hitting record high last week. For those readers who are looking for Singapore small caps which are overlooked by the market, Jiutian Chemical (“Jiutian”) may be an interesting company to […]

Analyst 11 Sep 20

Riverstone – Is the recent 32% decline justified? (12 Sep 2020)

Riverstone recently caught my attention. It has tumbled approximately 32% from an intraday high of $4.90 on 7 Aug 2020 to close $3.33 on 11 Sep 2020. One client even thought that Riverstone has already undergone a bonus issue! The recent weakness is likely attributed to its co-founder selling 15.5m shares at $3.95 (Bloomberg cites a 90-day lockup on seller); the possibility of a vaccine resulting in demand for gloves and consequently their average selling price (“ASP”) falling off the cliff and some Malaysia investors selling shares to raise cash, as their moratorium on loan repayment ends (click HERE for […]

Analyst 2 Sep 20

Wilmar – Is this a good time to accumulate? (2 Sep 2020)

Wilmar recently caught my attention. It has fallen approximately 11% from an intraday high of $4.95 on 7 Aug 2020 to close $4.41 on 1 Sep 2020. Six points attracted me to Wilmar. Let’s take a look. 1. Imminent catalyst i.e YKA IPO – left one approval to go Wilmar cited that its Chinese subsidiary, Yihai Kerry Arawana Holdings Co., Ltd (“YKA”), has obtained listing clearance from the Shenzhen Stock Exchange (“SZSE”) ChiNext Board Listing Committee (the “Committee”) and has submitted the updated prospectus to the China Securities Regulatory Commission (“CSRC”) for final registration approval for listing on SZSE ChiNext Board […]

Starburst chart as of 23 Aug 20

Starburst – building order books; bright outlook (24 Aug 2020)

In May 2019, I met Starburst’s Managing and Executive Director Mr Yap Tin Foo. Since Mar 2020, Starburst has been on a roll in winning contracts and I believe it is an opportune time to meet Mr Yap again. Despite Mr Yap’s busy schedule, he agrees to meet me on 1-1 basis to share his company’s business operations and prospects. Below are some of my takeaways from my discussion with him and from its recent results briefing.   Company description Quoting from Starburst’s press release, it is an engineering specialist in a niche industry, and designs, fabricates, installs and maintains […]

Bloomberg opposite directions share price, EPS Robert Burgeoss 16 Apr 20

S&P500 has rebounded 31% from 23 Mar 20! Time to buy, hold or sell (19 Apr 20)?

S&P500 has staged a whopping 683 points, or 31% rebound from its intraday low of 2,192 to close 2,875 on 17 Apr 20. Many clients have asked me (almost daily) whether we have already seen the bottom and is this a good time to buy stocks etc. At 2,875, S&P500 is just 15% away from its record intraday high of 3,394 on 19 Feb 2020. The rally in Wall Street is at a stark contrast to grim news from Main Street in terms of job losses; significant number of deaths from Covid 19; lockdowns and poor corporate results. Both bull […]

Table 1_Stock price performance for some tech stocks

Frencken nears 14Y overbought RSI level amid 10Y high prices (19 Nov 2019)

This week, Frencken has caught my attention with its 34% surge from $0.690 on 31 Oct 2019. It closed $0.925 on 19 Nov 2019. At $0.925, this is very near to its 10-year high closing price $0.930 set on 18 Nov 2019. Since 31 Oct 2019, it has risen 10 out of the past 13 trading days with two days having closed unchanged. RSI closed at 88.1 on 19 Nov 2019, which is near a 14 year overbought level. Based on Frencken’s chart, it seems to present a favourable risk to reward short trade. Please see the basis and more […]